Company intelligence / Profile preview

Viridia Life Sciences

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Viridia Life Sciences is developing proprietary, controllable formulations of DMT, aiming for optimized onset/offset of psychedelic experience for mental health indications. Clinical trials were planned for 2021. Progress beyond this stage is not detailed in available sources. Digital therapy partnership aims to enable remote patient monitoring and personalized treatment paradigms.

Therapeutic areas: Psychiatry
Modalities: Small moleculepsychedelic small molecules
Industry: Biotech

Partnerships

ATAI subsidiary Introspect for digital therapeutics

Beyond the preview

Go deeper on Viridia Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viridia Life Sciences.

Explore the full profile